-
PROVIDERS
Watch now
Are you getting the full picture? A webinar series on the power of comprehensive intelligent diagnostics
-
LIFE SCIENCES
ENROLL NOW
Tempus’ Patient-Derived Organoid ScreensEvaluate the efficacy of your preclinical compounds using fixed organoid panels designed for diverse therapeutic applications.Space is limited — enroll by June 30, 2025, to secure your spot.
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
ONCOLOGY /// CARE PATHWAY intelligence SOLUTIONs
Tempus Next Oncology
Tempus Next applies technology, data, and AI to enable precision medicine, empowering providers to deliver the next step in a cancer patient’s care journey.
Our Solution
Tempus Next: AI-enabled care pathway intelligence
Tempus Next applies technology, data, and AI to enable precision medicine, empowering providers to deliver the next step in a cancer patient’s care journey.
Identify and contextualize cancer patients in their care journey
AI-enabled solutions designed to surface deep insights from multimodal, longitudinal patient data including medical imaging data, EHR data, lab results, pathology reports and clinician notes.
Surface precision care pathways at the point of care
Tiered and customized notifications consistent with precision medicine guidelines in the physician’s workflow reduce alert fatigue.
Track patients for timely follow-up to help improve outcomes
Patient Tracking for patients with current disease who need management, Patient Lists to search for subsets of patients and Dashboards to track insights into a hospital’s patient population.
Monitor notification effectiveness and guidelines adoption
Institution-level insights reports delivered to hospital systems help understand effectiveness of the notifications and emerging trends in guideline adoption.
Increase equitable access to care
Timely and accurate diagnostics, procedures and therapies for all cancer patients, regardless of socioeconomic status.
Figure: In this study, black patients saw a larger decrease in average time from index echo to follow up (120 vs 64 days) compared to white patients (57 to 36 days), showing the improvement in black patients’ time to follow up towards the average seen in white patients’ (narrowing the gap).
Horde G, Sotelo M, D’Amico A, et al. Use of an echocardiographic-based, artificial intelligence system to improve racial disparities in care of patients with valvular heart disease. European Heart Journal – Cardiovascular Imaging. 2023;24(Suppl 1):38.3.
upcoming webinar
Navigating New Frontiers in Breast Cancer Care Pathway Intelligence: The Role of Providers and AI
Learn how Mercy Health System is using Tempus Next to support providers in delivering guideline directed and personalized breast cancer care.
Register nowCase Study
Closing the biomarker testing gap for early stage NSCLC (Non-small cell lung cancer) patients with Tempus NextLearn how Tempus Next was deployed at TriHealth Cancer and Blood Institute in Cincinnati, Ohio to surface and close gaps in biomarker testing for NSCLC patients.
LEARN MORE
Webinar
Using AI to identify and close gaps in care for cancer patientsLearn how TriHealth Cancer and Blood institute implemented Tempus Next to accelerate the adoption of precision care pathways for NSCLC patients.
Watch now
Improve adherence to clinical guidelines through AI-enabled and targeted notifications at the point of care.
This is data-driven precision medicine
This is the future of healthcare.